Sibutramine: Gone, but not forgotten

Practical Diabetes International

Volumn 27, Issue 3, 2010, Pages

  Haslam, David ^a  

^a LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; CONTRAVE; DAPAGLIFLOZIN; EMPATIC; LIRAGLUTIDE; LORCASERIN; PHENTERMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ACUTE HEART INFARCTION; BLOOD PRESSURE; BODY MASS; BOREDOM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IRRITABILITY; OBESITY; PRESCRIPTION; PULSE RATE; SHORT SURVEY; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 77952787196     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1453     Document Type: Short Survey

References (14)

1. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000; 356: 2119-2125.
2. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-1339. (Pubitemid 33015524)
3. Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-112. (Pubitemid 33072165)
4. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125-131.
5. Astrup A, Chong E. Weight loss produced by sibutramine: a metaanalysis. Int J Obes Relat Metab Disord 2001; 25(Suppl 2): S104.
6. James WS, Astrup A, Finer N, et al. Efficacy of sibutramine on weight maintenance after weight loss: a randomised trial: The STORM Study Group. Lancet 2000; 356: 2119-2125.
7. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508-515.
8. Abbott Laboratories. Sibutramine Summary of Product Characteristics.
9. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005; 7(Suppl L): L44-L48.
10. Caterson I, Sharma AM, Coutinho W, et al.; on behalf of the SCOUT Investigators. Does the risk profile of patients with cardiovascular disease and/or diabetes modify initial response to treatment with sibutramine? A preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Int J Obes 2008; 32(Suppl 1s): S100, Abstract T2:PS:80 (available at: www.nature.com/ijo/journal/v32/n1s/pdf/ijo200847a.pdf).
11. Lavie CJ, Milani RV, Artham SM, et al. The obesity paradox, weight loss, and coronary disease. Am J Med 12 Aug 2009 [epub ahead of print].
12. Strandberg T, Strandberg A, Salomaa V, et al. Explaining the obesity paradox: cardiovascular risk, weight change, and mortality during long-term follow-up in men. Eur Heart J 2009; 30: 1720-1727.
13. McAuley PA, Kokkinos PF, Oliveira RB, et al. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc 2010; 85(2): 115-121.
14. Dorner TE, Rieder A. Obesity paradox or reverse epidemiology. Dtsch Med Wochenschr 2010; 135(9): 413-418. [Epub 23 Feb 2010.]